BetterLife Pharma Inc. has appointed Doug Drysdale, former CEO of Cybin Inc., as Corporate Advisor to advance the company's product BETR-001 for non-psychiatric indications with focus on cluster headache and migraine. This appointment signals a strategic move to accelerate development of innovative neurological treatments using Drysdale's extensive pharmaceutical industry experience.
Drysdale brings significant credentials to BetterLife, having led Cybin from molecule inception to Phase 3 trials in just three years. His track record includes growing Alvogen from inception to $500 million in revenues across 35 countries within 5.5 years, establishing research and development operations in New Jersey and a contract research organization in India. His transformation of Norwich Pharmaceuticals and leadership at Pernix Therapeutics, where he grew enterprise value from $80 million to $800 million, demonstrates his capability in pharmaceutical company development and value creation.
Dr. Ahmad Doroudian, CEO of BetterLife, stated the company looks forward to working with Drysdale to develop BETR-001 for treatment of cluster headache, migraine and neuropathic pain. BETR-001 represents BetterLife's patented stereoisomer of 2-bromo-LSD, a non-hallucinogenic derivative of LSD. Previous forms of 2-bromo-LSD have been shown to be non-hallucinogenic, safe and tolerable in humans, with a small clinical study demonstrating meaningful reduction in cluster headache frequency according to research published in Cephalgia in 2010.
The significance of this appointment extends beyond corporate strategy to potential patient impact. BETR-001's development as a non-hallucinogenic and non-controlled LSD derivative means it could be self-administered, eliminating regulatory hurdles that typically accompany psychedelic-derived treatments. BetterLife's synthesis patent for BETR-001 and pending composition and method of use patent, which covers treatment of various neurological disorders until around 2042, provides substantial intellectual property protection.
For further information about the company's developments, investors and interested parties can visit BetterLife Pharma. The appointment of an executive with Drysdale's proven track record in pharmaceutical development and commercialization suggests accelerated progress toward clinical trials and potential new treatment options for patients suffering from debilitating neurological conditions like cluster headaches and migraines.
